Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...
Michigan’s pension bought Palantir, Intel, and CVS Health stock, while slashing an investment in Bristol Myers in the third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback